

Gibson Dunn Advising Damora Therapeutics on Sale to Galecto and on \$285 Million Private Placement by Galecto

Firm News | November 12, 2025

Gibson Dunn is advising privately held biotechnology company Damora Therapeutics, Inc. on its sale to Galecto, Inc. Gibson Dunn also advised on a concurrent \$285 million private placement by Galecto. Jefferies, Leerink Partners, UBS, and LifeSci are serving as the placement agents to Galecto. The Gibson Dunn corporate team includes partners Ryan Murr and Branden Berns and associates Evan Shepherd, Maggie Zhang, Chad Kang, and Anika Gidwani. Partner Melanie Neary and associates Nick Linke and Lauren Navarro advised on public company matters; partner Gina Hancock and associate Lucy Hong advised on employee compensation and benefits matters; and partner Pamela Lawrence Endreny and associate Ryan Rott advised on tax matters.

Related People

[Ryan A. Murr](#)

[Branden C. Berns](#)

[Evan Shepherd](#)

[Maggie Zhang](#)

[Chad Kang](#)

[Anika Gidwani](#)

[Melanie E. Neary](#)

[Nicholas G. Linke](#)

[Lauren Navarro](#)

[Gina Hancock](#)

[Lucy Hong](#)

[Pamela Lawrence Endreny](#)

[Ryan Rott](#)

Related Capabilities

[Life Sciences](#)

[Capital Markets](#)

[Executive Compensation and Employee Benefits](#)

[Tax](#)